Recruiting COVID-19 Studies in Tucson
RECOVER-SLEEP: Platform Protocol
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure tha...
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmun...
About COVID-19 Clinical Trials in Tucson
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus that primarily affects the respiratory system. Long COVID (PASC) involves persistent symptoms weeks or months after initial infection. Treatment includes antiviral medications, monoclonal antibodies, and supportive care.
There are currently 2 covid-19 clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 1,894 participants. Research is being sponsored by Duke University, University of Minnesota. Clinical trial participation is free and participants receive study-related medical care at no cost.
COVID-19 Clinical Trials in Tucson — FAQ
Are there covid-19 clinical trials in Tucson?
Yes, there are 2 covid-19 clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Tucson?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.
Are clinical trials in Tucson free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.
What covid-19 treatments are being tested?
The 2 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for covid-19.
Data updated March 2, 2026 from ClinicalTrials.gov